ArticleJournal of managed care & specialty pharmacy2026
Which drugs will Medicare negotiate next? Predicting selected drugs for Initial Price Applicability Year 2029.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe fourth cycle of the Medicare Drug Price Negotiation Program (MDPNP) for Initial Price Applicability Year (IPAY) 2029 will continue to include both Medicare Part B and Part D drugs while incorporating several important policy changes that affect eligibility and selection. These changes, including clarification of drug eligibility criteria, expiration of the temporary small biotech exception, and implementation of the biosimilar delay provision, may substantially influence which drugs are selected for negotiation.
objectiveTo predict the Medicare Part B and Part D 20 drugs most likely to be selected for IPAY 2029.
methodsUsing the Centers for Medicare & Medicaid (CMS) Medicare Part B and Part D drug-spending data from 2020 through 2024 and Average Sales Price 2025 pricing files, we projected 2025 gross Medicare expenditures (GMEs) using regression models incorporating historical use and pricing trends. Statutory exclusion criteria were applied consistent with the Inflation Reduction Act, the One Big Beautiful Bill Act, and the June 2026 CMS proposed rules to identify negotiation-eligible drugs and rank drugs by projected GME. A secondary forecasting approach incorporating unadjudicated quarterly Medicare Part B and Part D spending data through quarter 3 of 2025 was conducted to approximate the statutory CMS expenditure assessment period (November 1, 2025-October 31, 2026).
resultsFifty qualifying single-source drugs were identified. Twenty drugs, each with projected 2025 GMEs exceeding $500 million, were predicted to be selected for IPAY 2029. The primary and secondary forecasting approaches identified similar results, with 17 of the top 20 drugs appearing in both. Three drugs became newly eligible following expiration of the temporary small biotech exception. We also identified 27 drugs with projected 2025 GMEs exceeding $1 billion that remained ineligible because of statutory time on market or orphan drug exclusions as well as additional drugs potentially affected by the biosimilar delay provision.
conclusionsRecent legislative and regulatory changes continue to reshape eligibility for the MDPNP. These findings provide an updated framework for anticipating future negotiation cycles and demonstrate how evolving CMS policy may influence drug selection and the future implementation of the MDPNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.